Results reported in Mal. J. Nutr. paper, 'Potential of Mixed Tocotrienol Supplementation to Reduce Cholesterol and Cytokines Level in Adults with Metabolic Syndrome'
ExcelVite, the leading and only GMP-certified tocotrienol producer, is delighted to share another new human clinical study that uncovers the link between EVNol SupraBio — patented and bioenhanced full spectrum palm tocotrienol/tocopherol complex — and the reduction of LDL-cholesterol, diastolic blood pressure and inflammatory markers such as Interlukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) among metabolic syndrome subjects.
In this study, 70 adults with metabolic syndrome aged 20-60 were randomised to receive palm mixed tocotrienols (EVNol SupraBio) or a placebo for 16 weeks.
Anthropometric test, body composition, dietary intake, physical activeness and blood pressure were examined at baseline, week 8 and week 16. Blood cholesterol and inflammatory markers were determined at baseline and week 16.
When compared with baseline, subjects supplemented with tocotrienols showed a significant reduction of 13.9% and 10.6% for IL-6 and TNF-alpha inflammatory markers, respectively. Additionally, the diastolic blood pressure, total cholesterol and LDL-cholesterol also showed reduction by 5.4%, 4.6% and 5.3%, respectively.
'Metabolic syndrome is a cluster of risk factors and we are thrilled to know that subjects supplemented with EVNol SupraBio maintained a healthy range of cholesterol and blood pressure. To date, this is the first study to show that supplementation with tocotrienol attenuates the production of inflammatory markers such as IL-6 and TNF-alpha in metabolic syndrome subjects.
'Both IL-6 and TNF-alplha are strongly associated with obesity induced inflammatory processes, which constitute the main contributing factor to metabolic syndrome,' says CheeYen Lau, Nutritionist at ExcelVite. 'Tocotrienol is scarce in nature. Therefore, it is highly recommended to consume food or beverages fortified with tocotrienol or dietary supplements to attain the biological effective dosage for health maintenance.'
'However, one drawback about tocotrienol is that, being a fat-soluble compound, tocotrienol has been proven to have erratic and poor absorption in human. As such, high concentration or dosage of tocotrienol (from a regular oil extract) may not confer the intended health benefits if the tocotrienols are not being absorbed,' added CheeYen.
EVNol SupraBio was developed to ensure increased oral absorption of each tocotrienol isoforms of up to 300% when compared with regular tocotrienol oil extract. In this regard, EVNol SupraBio achieves therapeutic blood level at a lower dosage of supplementation, and thereby delivering tocotrienols to cells effectively for their health beneficial properties.